Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP703 | DOI: 10.1530/endoabs.81.EP703

ECE2022 Eposter Presentations Pituitary and Neuroendocrinology (211 abstracts)

The clinical implication of macroprolactinemia detection using PEG 6000 in a group of women of childbearing-age with hyperprolactinemia in sub-Saharan Africa: experience of a tertiary hospital

Anne Ongmeb Boli1, Mendane Ekobena Francine2, Etoa Etoga Martine1, 2, Charly FEUTSEU3, Mbono Samba Esther Aristide1,2, Falmata Amazia4, Djahmeni Éric Noël1, Ndi Manga Arnaud1, Katte Jean Claude1, Dehayem Mesmin1, 2, Ama Moor Vicky Jocelyne5 & Sobngwi Eugène1,2


1Yaounde Central Hospital, National Obesity Centre, Endocrinology and Metabolic Disease Unit, Yaoundé, Cameroon; 2University of Yaoundé 1, Faculty of Medicine and Biomedical Sciences, Department of Internal Medicine and Specialities, Yaoundé, Cameroon; 3University of Yaoundé 1, Biotechnology Centre, Yaoundé, Cameroon; 4University of Yaoundé 1, Faculty of Medicine and Biomedical Sciences, Doctoral School of life, Health and Environnemental Sciences, Yaoundé, Cameroon; 5University of Yaoundé 1, Faculty of Medicine and Biomedical Sciences, Department of Biochemistry, Yaoundé, Cameroon


Introduction: Macroprolactin (MacroPRL), a variant of human prolactin may interfere with hormonal assay and falsely increase serum prolactin levels. Therefore, failure to identify macroprolactinemia can lead to inappropriate investigations and treatment in women who are already susceptible to anxiety and stress. We aimed to identify macroprolactinemia among women of childbearing age with hyperprolactinemia.

Materials and methods: We conducted a cross-sectional study at the endocrine unit of one of the tertiary hospitals in Cameroon. Study participants were recruited from both endocrine and gynecological outpatient consultations services. They were women of childbearing age (18 to 49 years) consulting for signs and symptoms of gonadal dysfunction or hyperprolactinemia (PRL >25 ng/ml). Total prolactin was measured using a Human direct ELISA method. Polyethylene glycol 6000 (PEG 6000) precipitation was used to detect macroprolactinemia.

Results: We enrolled 33 women with a mean age of 31 ± 7 years (range 21-48). Twenty-seven (81.8%) participants were symptomatic with the majority 23/27 (69.7%) reporting galactorrhea and 21 (63.4%) women reported having an irregular menstrual cycle. The median pre-precipitation prolactinemia reduced significantly after PEG precipitation from 61.2 (IQR: 33.2-115.9) ng/ml to 33.8 (IQR: 17.9-70.5) ng/ml, P< 0.001. After PEG precipitation, 5 participants had a serum prolactin recovery rate below 60%, and therefore a prevalence of macroprolactinemia at 15.2%. Four (80%) women with macroprolactinemia presented with symptoms, and there was no association between macroprolactinemia and symptoms of hyperprolactinemia among these participants.

Conclusion: Macroprolactinemia was detected in 5/33 (15.2%) of the study population. There was no association between macroprolactinemia and symptoms of hyperprolactinemia. Oligomenorrhoea, amenorrhoea, and galactorrhea were present in the majority of patients with macroprolactinemia hence routine screening for macroprolactinemia is recommended or advised in order to reduce the use of dopamine agonist treatment and imaging.

Keywords: Prolactin, Macroprolactin, PEG, Prolactin recovery rate, hyperprolactinemia

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.